Work

IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps3111

Authors: Anthony W. Tolcher, David S. Hong, Ryan J. Sullivan, James Walter Mier, Geoffrey Shapiro, Joseph Pearlberg, Les H. Brail, Jahnavi Kharidia, Lixin Han, Claudio Dansky Ullmann, Howard Marvin Stern, Jedd D. Wolchok

Institutions: South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Dana-Farber Cancer Institute, Infinity Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2697993777

Cites:

Cited by: 7

Related to: 10